Fortis Healhcare

Private hospitals to expand bed capacity, focus on oncology in FY26

Rising demand for cancer beds, healthy growth signs in ARPOB fuel expansion plans

Fortis Healthcare Q3 results: Net profit jumps 89% to Rs 254 crore

Fortis Healthcare Ltd on Friday reported an 89 per cent jump in consolidated net profit to Rs 254.3 crore in the December quarter, boosted by exceptional item gains. The company had posted a consolidated net profit of Rs 134.23 crore in the same quarter last fiscal, Fortis Healthcare Ltd (FHL) said in a regulatory filing. Consolidated revenue from operations in the third quarter stood at Rs 1,928.26 crore against Rs 1,679.68 crore in the year-ago period, it added. During the quarter, the company had exceptional item gain of Rs 23.5 crore from the sale of Richmond Road Hospital, Bengaluru and Rs 30 lakh from reversal of allowance of interest accrued receivable from Fortis C Doc Healthcare Ltd, the filing said. Total expenses were higher at Rs 1,695.62 crore in the October-December quarter compared to Rs 1,515.58 crore in the corresponding period last fiscal, the company said. "We have continued our positive momentum in Q3 with the hospital business contributing approximately 84 per

UBS Group buys shares of 29 firms including Reliance for Rs 1,938 cr

Swiss investment bank UBS Group on Friday bought shares of 29 companies, including Fortis Healthcare, Max Financial Services, Reliance Industries, Blue Star and Hyundai Motor India, for Rs 1,938 crore through open market transactions. According to the block deal data available on the National Stock Exchange (NSE), UBS AG purchased shares of Fortis Healthcare worth Rs 164 crore, bought shares of Max Financial Services for Rs 144 crore, and of Reliance Industries for Rs 138 crore. Additionally, UBS also picked up shares of Blue Star for Rs 120 crore and acquired shares of Hyundai Motor India for Rs 103 crore. The Swiss multinational also picked up shares in companies including One97 Communications, Zomato, Tata Consultancy Services and others. The shares were acquired at a combined transaction value of Rs 1,937.71 crore. Meanwhile, UBS Group's affiliate UBS Principal Capital Asia Ltd offloaded the same number of shares of 29 companies at the same price. Shares of Fortis Healthcare

Biocon, Marico among 5 mid-, small-cap stocks holding fort in a weak market

The overall market trend has been negative with over 60% of the Nifty Mid- and Small-Cap stocks now trading below the long-term moving averages; however, these 5 stocks continue to buck the trend.

Fortis Healthcare appoints Leo Puri as new Chairman its Board of Directors

At present, Puri serves on the boards of industry-leading organisations, including Tata Sons, Hindustan Unilever, and Dr. Reddy's Laboratories, further demonstrating his extensive expertise

No plans to list diagnostic arm Agilus Diagnostics: IHH Healthcare

Engaging with regulator on open offer for 26.1% stake in Fortis

Fortis Health hits 52-week high on plans to buy 32% stake in subsidiary

Fortis Healthcare's stock price today surged after the healthcare company said that it will buy the entire 31.52 per cent stake held by private equity investors in the material wholly owned subsidiary

Fortis Healthcare to acquire 31% stake in Agilus for Rs 1,780 crore

Deal values diagnostic arm at Rs 5,700 crore

Fortis Healthcare Q1 results: Profit rises 40% over hospital biz growth

The company's revenue from operations rose to Rs 1,859 crore in Q1FY25, a 12.2 per cent Y-o-Y rise from Rs 1,657 crore reported in Q1FY24

PE firm Blackstone likely to own majority in Aster-Care merged entity

While the unlisted Quality Care India is valued at around Rs 16,826 crore ($2 billion) by bankers, Aster DM Healthcare's total market valuation was Rs 18,424 crore as of Monday

Nomura ups target price for Fortis, sees 12% upside; reiterates 'Buy'

The global brokerage firm maintained its 'Buy' call for Fortis Healthcare with an updated twelve month forward target price of Rs 547, a 12 per cent upside to Monday's close

IndiGo, HCLTech, JK Lakshmi Cement among nine stocks to track on May 24

On Thursday, US markets closed in the red as robust economic data dashed hopes for Federal Reserve rate cuts

Q4 results today: IndiGo, ITC, and Fortis among 181 firms to post earnings

Company Q4 FY24 results today: ICRA, Rupa & Company, Page Industries, and Shilpa Medicare will also release their fourth quarter earnings report on May 23

Stocks to Buy: Here's why Angel One is bullish on Fortis, Piramal Pharma

Stocks picks by Angel One: Fortis Healthcare is in a secular uptrend, hovering above its EMAs (Exponential Moving Average) on the daily time frame chart

Fortis Healthcare Q3 results: Profit down 3.2%, revenue grows by 7.7%

The company reported a fall in bed occupancy to 64 per cent in Q3FY24, from 66.1 per cent in the same quarter last year. This has been attributed to the addition of 100 operation beds

Fortis Healthcare plans acquisitions, may opt for neutral brand name

We have taken a calculative view that at least for SRL, we have moved to the Agilus brand, and we have successfully completed that last year, said CFO of Fortis Healthcare

Fortis launches institute for specialised treatment of blood cancer

A well-known private healthcare group, Fortis on Friday inaugurated a state-of-the-art facility for the specialised treatment of blood cancers and disorders, which it said "represented a critical step" in addressing the urgent need for comprehensive holistic care. The Fortis Institute of Blood Disorders also integrates paediatric and geriatric care, advanced transplant procedures, and hematopathology expertise, all under one roof, Fortis Healthcare said in a release. The Institute also launched CAR-T cell therapy to its extensive network of Bone Marrow Transplant centres in Mohali, Delhi, Gurgaon, Noida, Mumbai and Bangalore, the statement said. This initiative is supported by a commercial collaboration with ImmunoACT, an IIT-Bombay spin-off and pioneer in India's first fully indigenous and commercially approved gene-modified cell therapy. The NexCAR19, India's first market-authorised CAR-T cell therapy, offers a new ray of hope for treating B-cell lymphomas and B-acute lymphoblast

As Covid-19 cases rise in India; should you keep pharma stocks on radar?

Barring Dr Lal Pathlabs, the other four healthcare related stocks listed below seem to be trapped in a range for now, charts suggest.

Hospitals see 7-8% surge in patient footfall, new investments in 2023

Jose told Business Standard that investments in medical equipment and increasing bed capacities have picked up in 2023 after a hiatus during the Covid19 period

Fortis Healthcare Q2 results: Net profit declines 15% to Rs 173.7 crore

The company declared results post-market hours. Fortis Healthcare Limited stock was up by 17 basis points (5 per cent) on the BSE to Rs 359.15 apiece